UConn Health’s Neag Comprehensive Cancer Center is one of a few centers nationwide recruiting patients for a new clinical trial testing a novel immunotherapy’s ability to battle the most common and aggressive form of primary liver cancer called hepatocellular carcinoma.

At UConn Health the experimental intravenous immunotherapy medication OX40 of Pfizer (PF-04518600) is in the earliest phase of clinical trial testing for safety and efficacy. The immune stimulating drug fights cancer by binding to the OX40 ligand on immune system T Cells to help them rapidly multiply and live longer to hunt for and kill spreading cancer cells.